Aishwarya Mary Johnson

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Signaling Pathway

Top Venues

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Aishwarya Mary Johnson, Sara Jose, Abdul Rasheed Palakkott, Farheen Badrealam Khan, Nanthini Jayabalan, Jaleel Kizhakkayil, Shamma Abdulla Ali AlNaqbi, Mark Gh Scott, Mohammed Akli Ayoub, Richard Gordon, Hariharan Saminathan
Pharmacological Inhibition of PTEN Rescues Dopaminergic Neurons by Attenuating Apoptotic and Neuroinflammatory Signaling Events. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (2023)
Hayate Javed, Aishwarya Mary Johnson, Anil Kumar Challagandla, Starling Emerald Bright, Safa Shehab
Cutaneous Injection of Resiniferatoxin Completely Alleviates and Prevents Nerve-Injury-Induced Neuropathic Pain. Cells 11 (24) (2022)
Hayate Javed, Aishwarya Mary Johnson, Anil Kumar Challagandla, Starling Emerald Bright, Safa Shehab
Cutaneous Injection of Resiniferatoxin Completely Alleviates and Prevents Nerve-Injury-Induced Neuropathic Pain. Cells 11 (24) (2022)
Hayate Javed, Aishwarya Mary Johnson, Anil Kumar Challagandla, Starling Emerald Bright, Safa Shehab
Cutaneous Injection of Resiniferatoxin Completely Alleviates and Prevents Nerve-Injury-Induced Neuropathic Pain. Cells 11 (24) (2022)
Hayate Javed, Aishwarya Mary Johnson, Anil Kumar Challagandla, Starling Emerald Bright, Safa Shehab
Cutaneous Injection of Resiniferatoxin Completely Alleviates and Prevents Nerve-Injury-Induced Neuropathic Pain. Cells 11 (24) (2022)
Hayate Javed, Aishwarya Mary Johnson, Anil Kumar Challagandla, Starling Emerald Bright, Safa Shehab
Cutaneous Injection of Resiniferatoxin Completely Alleviates and Prevents Nerve-Injury-Induced Neuropathic Pain. Cells 11 (24) (2022)
Aishwarya Mary Johnson, Robert Barigye, Hariharan Saminathan
Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. Human vaccines & immunotherapeutics 17 (9) (2021)